Clinical Stage Opportunity Epigenetix is a clinical stage biotech with a first-in-class oral cancer drug entering phase trials at multiple top US centers, indicating a potential need for CROs, trial logistics, biomarker analytics, and regulatory consulting support.

Targeted Collaboration The drug targets p300/CBP, BRD4, and CECR2 with potential synergy with checkpoint inhibitors and other therapies, suggesting opportunities for partner procurement of combination therapy studies, companion diagnostics, and translational research partnerships.

Funding Signals Revenue in the low to mid single digits and a lean headcount imply budget constraints but openness to strategic partnerships, licensing deals, and sponsored research arrangements with larger biotech, pharma, or contract organizations.

Technical Stack Existing reliance on WordPress, LiteSpeed, and standard web tools indicates potential for digital-related services, including website optimization for investor communications, clinical trial recruitment landing pages, and regulatory documentation portals.

Geographic & Market Fit Based in Delray Beach with engagements at five leading US cancer centers, Epigenetix is positioned for US market expansion partnerships, clinical operations outsourcing, and access to US-based CRO networks and oncology-focused distribution channels.